ISPE NORDIC CONFERENCE STOCKHOLM, SWEDEN
|
|
- Neil Scott
- 7 years ago
- Views:
Transcription
1 ISPE NORDIC CONFERENCE STOCKHOLM, SWEDEN 26 th MAY 2016 ÅF BUILDING, FRÖSUNDALEDEN 2, SOLNA. EU GMP Annex 15 Qualification & Validation and Continuous Process Verification
2 Prepare yourself for tomorrow s pharmaceutical production In October 2015 the revised EU GMP Annex 15 regarding Qualification and Validation was released. This ISPE Nordic seminar will highlight the changes from a regulatory perspective. The seminar will also present Continuous Process Verification (CPV) and how this is approached by our industry. During the conference, you will be given the opportunity to see and learn from others who have implemented the new requirements in a production environment. The seminar will be held in Stockholm May 26, and is one of few opportunities in the area to objectively learn more about a new mandatory regulation we all must adapt to. The ISPE PQLI Guide: Part 4 The ISPE PQLI Guide: Part 4 Process Performance and Product Quality Monitoring System serves as practical how-to guidance with examples of technical and scientific methodology for adopting a process performance and product quality monitoring system (PP&PQMS) in line with the expectations of ICH Q10, Pharmaceutical Quality System. By establishing a PP&PQMS, your company can improve opportunities to: Maintain compliance with global regulations Improve confidence that a process runs as intended The Guide introduces the role of Quality Steward as an owner of product quality. Responsibilities of the role are discussed for this new concept emerging from industry This PQLI Guide is relevant for: New and existing products Small and large molecule All phases of product lifecycle, from development through product discontinuation 2
3 Conference program 26 May :00-08:30 08:30-08:45 08:45-09:45 09:45-10:45 10:45-11:00 11:00-12:00 12:00-12:30 12:30-13:30 13:30-14:30 14:30-14:45 14:45-15:45 15:45-16:00 16:00-17:00 Registration and Coffee Welcome and introduction General update and requirements of Annex 15 and CPV Inger Jönebring, Senior GMP Consultant, MedIQ Consulting AB Seamless integration of ASTM E2500, Annex 15, FDA Process Validation Guid line and Chinese GMP in large CapEx project in China Daniel Nilsson, Senior Management Consultant, Aregab AB Network break The Real Challenge of Annex 15 Continuous Process Verification: Case Study Dr. Lorenz Liesum, Lead Process Analytical Technology (PAT), Novartis Pharma AG Lunch The bridge between the traditional and a new live cycle validation approach and the way to the continuous process verification Timur Güvercinci, Head of Validation, Qualification & Engineering, Merck KGaA Designing a Risk Based, Efficient Approach to Ongoing/Continued Process Verification Tara Scherder, Managing Director, Arlenda Inc. Network break Implementing CVP in smaller organisations Monica Hueg/ Vibeke Brun Jensen, NNE Pharmaplan Short Wrap Up Networking refreshments and snacks 3
4 About the presentations General update and requirements of Annex 15 and CPV Inger Jönebring, Senior GMP Consultant, MedIQ Consulting AB EurdraLex Volume 4, Annex 15 Qualification and Validation has been updated and was effected 1 October The previous version of Annex 15 of the EU Guide to GMP was published in September 2001, and since then there have been significant changes in the GMP environment and there have been advancements in manufacturing technology and continuous manufacture processes. Guidelines from the International Conference on Harmonisation (ICH), US FDA Guide on Process Validation, as well as the approaches in ASTM E Standard Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment have also justified the change. This presentation will give you the major changes and additional section in the updated version of Annex 15. Seamless integration of ASTM E2500, Annex 15, FDA Process Validation Guideline and Chinese GMP in large CapEx project in China Daniel Nilsson, Senior Management Consultant, Aregab AB Previously very few pharmaceutical manufacturers in China have aimed to launch their products in EU or the US. This situation is changing rapidly. This case study presents a case where a new facility for a biosimilar product has been designed, built, qualified and validated with state-of-theart risk management methods to US and EU standards, probably for the first time in China. In order to achieve this, a seamless project execution model was developed to span the entire process life cycle, from process design through validation and continued (and continuous) process verification. Throughout this project it became evident that there are challenges in deploying quality risk management in an emerging market. It also became evident that modern approaches to validation are effective leadership tools and can help establish a corporate quality culture. The Real Challenge of Annex 15 Continuous Process Verification: Case Study Dr. Lorenz Liesum, Lead Process Analytical Technology (PAT), Novartis Pharma AG Annex 15 offers continuous process verification as an alternative approach for process validation. As prerequisites for this alternative the guideline mentions one of hand product development according to QbD principle and on the other hand a science based control strategy with a recommendation to make use of process analytical technology tools. In this case study, the validation approach of the process and the related control strategy will be presented. Furthermore life cycle management aspects as maintenance and change control will be highlighted. In the context of life cycle management, strategies for ongoing process verification will be elaborated. 4
5 About the presentations The bridge between the traditional and a new live cycle validation approach and the way to the continuous process verification Timur Güvercinci, Head of Validation, Qualification & Engineering, Merck KGaA In the last 10 years the work of the International Council for Harmonization (ICH) had a huge influence to specific processes in the pharmaceutical industry, like the Quality Guidelines Q8 Pharmaceutical Development, Q9 Quality Risk Management and Q10 Pharmaceutical Quality for the process validation. The US and the EU authorities reacted with the rework of their requirements for process validation. The most of the pharmaceutical companies go true several lesson and learn activities to reach the knowledge for the adjustment of their processes, systems and facilities to fulfill these requirements. Designing a Risk Based, Efficient Approach to Ongoing/Continued Process Verification Tara Scherder, Managing Director, Arlenda Inc. To improve the likelihood of a successful monitoring program, it is critical that manufacturers focus on the real goals and understand how it is more than a textbook case of control charts. Otherwise, the process can become unnecessarily complex, requiring an unwarranted and unsustainable amount of resources. Ongoing monitoring is then seen as a business burden, instead of a process with real potential for both patient and business benefit. In this session, critical characteristics of pharmaceutical manufacturing data that must be understood to avoid wasteful over-complication or overreaction are discussed. These are presented within a framework for a risk based and efficient approach to the design and interpretation of control charts, parameter choice, and monitoring frequency. The mindset of both manufacturers and health authorities necessary to achieve the real goals of ongoing monitoring is explored. Implementing CVP in smaller organisations Monica Hueg/ Vibeke Brun Jensen, NNE Pharmaplan FDA s Guidance for Industry Process Validation: General Principles and Practices was drafted in November 2008 and was in force in January The document conveys FDA s current thinking on validation. EMA s Guideline on process validation for finished product information and data to be provided in regulatory submissions was drafted in February 2012 and was in force in February Keynotes for both guidance documents are: Process validation, continuous process verification (CPV), on-going process verification (OPV), critical process parameter, critical quality attribute, manufacturing process lifecycle and change control. It is expected by both regulatory bodies that these concepts and principles are implemented by the manufactures, but it seems, as there is some resistance in the industry for implementing these concepts and principles. The regulatory bodies had tried to make the validation process operational and data driven, but why has it then become so complex and difficult to implement CPV/OPV? is it because there are differences in expectations? Or is it just difficult to change the mindset and behavior? The question is therefore how can these requirements be achieved? The presentation gives an example from a smaller non-us company how CPV/OPV can be realized especially where to start with CPV/OPV for legacy product. 5
6 About the speakers Inger Jönebring Senior GMP Consultant, MedIQ Consulting AB Inger Jönebring works as a Senior GMP Consultant at MedIQ Consulting AB. Inger has approximately 18 years of good manufacturing practice (GMP) and validation experience within the pharmaceutical and biotech industry mostly in Sweden. For the last 10 years she has been working as a consultant as GMP & Validation specialist, Project Manager and QA-approver at several customers of different size. Inger has worked 14 years at quality control laboratories within the pharmaceutical-, biotech- and food industry with e.g. qualification of analytical instruments, Process Analytical Technology. Inger has a Master of Science with a major in Analytical Chemistry (Chemometrics) from the Stockholm University. Daniel Nilsson Senior Management Consultant, Aregab AB Daniel has worked in the Pharmaceutical and Biotech industry for more than 15 years. Currently he is working as a management consultant in Strategy and Business Transformation in Stockholm, Sweden. Daniel has recently relocated back to Sweden from Shanghai, China, after a long term assignment as director of the business area GMP and Validation Services for Pharmadule Morimatsu in Shanghai, China, where he and his team assisted domestic Chinese companies in reaching compliance with Chinese, WHO, EU and US GMPs, as well as supporting international organizations in navigating the opportunities and challenges of the Chinese Life Science market. Over the years Daniel has worked in projects in many parts of Europe and the United States. Dr. Lorenz Liesum Lead Process Analytical Technology (PAT), Novartis Pharma AG Leading a team within Global Pharma Engineering for : - Implementation of PAT methods in production - Supporting QbD submissions - Usage of MVDA (Multivariate Data Analysis) for on-line monitoring as well as for root cause and trend analysis - Providing technical engineering support Timur Güvercinci Head of Validation, Qualification & Engineering, Merck KGaA Timur Güvercinci is a pharmaceutical engineering with extensive experience in validation in the pharmaceutical and medical device industry. Timur graduated from Albstadt-Sigmaringen University in Germany with a graduate engineer of pharmaceutical engineering. As the Head of Validation, Qualification and Engineering in the Quality Assurance at Merck Biopharma (Darmstadt, Germany) he is responsible for the local validation requirements by the company. Timur has been working for several years in the pharmaceutical and medical device industry in various quality positions in different companies, where he had the opportunity to learn the implementation of validation requirements in different sectors of the industry. Tara Scherder Managing Director, Arlenda Inc. Has over 25 years of experience in the chemical and pharmaceutical industries as a statistician, process engineer, and master black belt. She has functioned as both an in-house and external statistical consultant to vaccine, API, and pharmaceutical manufacturing teams across the product lifecycle. Her current focus is the implementation of statistical methods and associated business processes for lifecycle process validation. She is passionate about teaching others the value and application of statistical methods. Tara s formal education includes a BS degree in Chemical Engineering from the University of Pittsburgh and a MS degree in Statistics from Carnegie Mellon University. She is the Chief Scientific Officer of Supply for Arlenda, Inc. Arlenda partners with clients in the pharmaceutical industry to leverage information to accelerate development, improve processes, and assure quality. 6
7 About the speakers Monica Hueg NNE Pharmaplan Monica Hueg is a Global Technology Partner within GMP and compliance at NNE Pharmaplan. She has more than 15 years of experience with production and construction of biotech, pharmaceutical and medical device facilities. During her professional career, Monica has built a broad and solid palette of theoretical expertise and practical experience within GMP and compliance. She has applied her ability to analyse, plan, implement and complete tasks in a wide range of projects within the pharma industry globally. For the past five years Monica s focus has been on providing consultancy services to facilitate strategic business decisions with special focus on quality and compliance. For instance, she has provided consulting in high-end strategic planning for future improvements to ensure compliance going forward often in connection with compliance gap analysis/assessments. Furthermore, Monica regularly teaches courses within GMP and compliance and has also developed a number of educational courses. Vibeke Brun Jensen NNE Pharmaplan Vibeke Brun Jensen is Director for the Compliance Consulting department at NNE Pharmaplan. She has more than 19 years of experience in regulated companies and has extensive knowledge of GMP guidelines and medical device and drug regulations issued by FDA and local European medicines agencies and ISO standards. Vibeke s focus is on implementation and assessment of quality management systems and critical quality process. Vibeke helps facilitate strategic business decisions with special focus on quality and compliance in both the pharma and the medical device industry and has taken roles as: project manager in GMP compliance projects GMP consultant, developing and implementing global validation strategies Subject matter expect on validation responsible for aseptic production in charge of implementing new equipment 6
8 Registration Registation is done here: Please register before on: Conference Fee Category ISPE Member Non Member Industry * Academia, Regulatory & YP * Students * *) Includes one year ISPE membership Tabletop Exhibition This conference is an excellent opportunity to meet people working with all kinds of aspects within Pharmaceutical Production. We can offer a limited number of table top exhibition possibilities for only 400 (excl. conference fee). Contact us for further information. Location ÅF building, Frösundaleden 2, Solna. Approximately 10 minutes walk from the commuter train station Solna Station. Questions regarding the event: Anna Kälvemark, ComplyiT, (ISPE Nordic Affiliate), anna.kalvemark@complyit.se Phone:
Engineering for the new pharma reality
NNE Pharmaplan is an international company specialised in pharma engineering. We help pharmaceutical companies bring products to market by providing flexible, compliant and future-proof solutions. We have
More informationApplication of new technology from a GAMP perspective
INVITATION ISPE GAMP Nordic Conference Application of new technology from a GAMP perspective Copenhagen 20 March 2014 at 09:00-16:30 The venue will be held at Novo Nordisk s new Domicile Building NN-1,
More informationProcess Validation: Practical Aspects of the New FDA Guidance
Process Validation: Practical Aspects of the New FDA Guidance ISPE Boston Chapter Meeting April 18, 2013 Rusty Morrison Commissioning Agents, Inc. Objectives / Summary What is Process Validation? Regulatory
More informationState of Control Over the Lifecycle and Process Validation (New and Legacy Products)
State of Control Over the Lifecycle and Process Validation (New and Legacy Products) Grace McNally Branch Chief (acting), Regulatory Policy and Collaboration Branch FDA/CDER/Office of Compliance ICH Q10,
More informationICH Public Meeting. Joseph C. Famulare. October 2, 2006. Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance
ICH Public Meeting October 2, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance The Current State of Pharmaceutical Manufacturing Inability to predict
More informationWelcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to
Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to introduce you to the concepts behind risk-based monitoring,
More informationGMP Pharma BV. Netherlands
GMP Pharma BV Netherlands Connecting the European & Indian Pharmaceutical, Biotechnology and Biopharmaceutical Industry for parallel growth and solicitation. About Us: GMP Pharma BV is a multisource organization
More informationComputerised Systems in Analytical Laboratories
ECA Certified Computer Validation Manager Course* New EU Annex 11 and Chapter 4 Requirements will be covered Computerised Systems in Analytical Laboratories Foto: DRK The Electronic Analytical GMP : Integrating
More information3rd ANNUAL SEMINAR PHARMASSIST Ltd in collaboration with PHARMA D&S Srl
Venue: To be announced 3rd ANNUAL SEMINAR Quality Risk Management & Quality Risk Management (ICH Q9) & Applications in the Pharmaceutical Quality System (ICH Q10): Applications in the Pharmaceutical Sector
More informationICH guideline Q10 on pharmaceutical quality system
September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final
More informationProcess Validation Guidance Requirements (FDA and EU Annex 15: Qualification and Validation)
Global CompliancePanel Knowledge, a Way Forward 2-day In-person Seminar: Process Validation Guidance Requirements (FDA and EU Annex 15: Qualification and Validation) Los Angeles, CA July 28th & 29th, 2016
More informationPHARMACEUTICAL QUALITY SYSTEM Q10
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step
More informationGuidance for Industry. Q10 Pharmaceutical Quality System
Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation
More informationHow companies leverage quality and quality certifications to achieve competitive advantage
How companies leverage quality and quality certifications to achieve competitive advantage Eize de Boer Systems & Services Certification International Business Development Manager Pharma Supply Chain for
More informationICH Q10 - Pharmaceutical Quality System
WCC PDA Dinner Meeting Jan 2012 ICH Q10 - Pharmaceutical Quality System Neil Wilkinson NSF-DBA www.nsf-dba.com ICHQ10.1 WCC PDA Dinner Meeting Jan 2012 Your Presenter Partner at NSF-DBA USA Training, Consultancy,
More informationImplementing Lifecycle Validation Practices at Contract Manufacturing Organizations
Implementing Lifecycle Validation Practices at Contract Manufacturing Organizations This paper discusses the nuances of lifecycle validation implementation at contract manufacturing organizations (CMOs).
More informationCONCEPT HEIDELBERG. Pharmaceutical Quality Training. Conferences. Services.
CONCEPT HEIDELBERG Pharmaceutical Quality Training. Conferences. Services. About Us Helping you to Comply with GMP Since our foundation on 1 April 1978, CONCEPT HEIDELBERG has been concentrating on providing
More informationPharmaceutical Engineering: The Lisbon Masters Program
EAFP Catania June 24-26, 26, 2010 Pharmaceutical Engineering: The Lisbon Masters Program José Menezes, Rogério Gaspar, João Bordado,, José Morais Technical University of Lisbon (Portugal) Faculty of Pharmacy,
More informationAn FDA Perspective on Post- Approval Change Management for PAT and RTRT
An FDA Perspective on Post- Approval Change Management for PAT and RTRT IFPAC 2015 January 26, 2015 Christine M. V. Moore, Ph.D. Acting Director, Process and Facilities FDA/CDER/OPQ Post-Approval Changes
More informationOOS investigations in a GMP environment
PharmaTraining and PMcG Consulting present - OOS investigations in a GMP environment 17 & 18 October 2016 UK Course objectives This course is designed to provide essential training for conducting Out of
More informationGuideline on Process Validation
1 2 3 4 29 March 2012 EMA/CHMP/CVMP/QWP/70278/2012-Rev1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 Draft Draft Agreed by CHMP /
More informationGE Healthcare Life Sciences. Validation Services. Compliance support through life cycle management
GE Healthcare Life Sciences Validation Services Compliance support through life cycle management Validation Services Validation Services is an independent product and service provider within GE Healthcare
More informationNEW CHEMICAL ENTITIES
NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product
More informationPharmaceutical Quality Management System: Current Concept
Pharmaceutical Quality Management System: Current Concept Neetu Dubey 1, *, Himanshu Gupta 3, R.K. Sharma 2, Nitin Dubey 1, Nidhi Dubey 4 1. IPS Academy, Indore, Madhya Pradesh, India. 2. Prestige Institute
More informationQUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate
More informationIn 2001, ISPE issued Baseline Guide Volume
In today s biopharma and pharmaceutical industries, three related, but distinct terms are in common use: commissioning, qualification, and verification. Inconsistent interpretation and application of these
More informationRecent Updates on European Requirements and what QPs are expected to do
Recent Updates on European Requirements and what QPs are expected to do QP Forum 28/29 November 2013, Lisbon Dr. Bernd Renger Modified: Georg Goestl 1 Written Conformation for API-Import Actual Status
More informationA NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program
A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry CLEANING VALIDATION Instructors Loh Kean Chong Rick Ng Date and Time
More informationGAMP5 - a lifecycle management framework for customized bioprocess solutions
GE Healthcare Life Sciences GAMP5 - a lifecycle management framework for customized bioprocess solutions imagination at work GE Healthcare s engineering department, Customized Bioprocess Solutions (CBS),
More informationThe Technical Compliance Manager
The Technical Compliance Manager Avoiding Non-Compliance in the technical area 3-5 June 2014, Berlin, Germany SPEAKERS: Dr Gerhard Hauser European Hygienic Engineering and Design Group (EHEDG) Dr Jean
More informationTitle:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions
WELCOME Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions Contents: Introduction GMP Audit GMP Audit plan GMP Auditing
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More informationSage ERP I White Paper
The Premier Provider of Effective Business Software Solutions National Presence, Local Touch 1.800.4.BLYTHE www.blytheco.com I White Paper Proactive Regulatory Compliance for Biopharmaceutical Global Competitiveness
More informationElectronic GMP Systems
Electronic GMP Systems Specification - Implementation Validation 18 20 March 2015, Prague, Czech Republic SPEAKERS: Kai Kiefer fme AG, Germany Dr Bob McDowall McDowall Consulting, UK LEARNING OBJECTIVES:
More informationICH Q7 GMP for Active Pharmaceutical Ingredients
National University of Singapore Academy of GxP Excellence (NUSAGE) and PharmEng Technology Presents ICH Q7 GMP for Active Pharmaceutical Ingredients Part of the Pharmaceutical Biotechnology Training Courses
More informationRegulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG
Regulatory Affairs Graduate Postgraduate Program Novartis Pharma AG Novartis Animal Health AG The Regulatory Affairs (RA) Graduate Program is an opportunity to discover the global functions of Drug Regulatory
More informationFinal Business Plan Q10: Pharmaceutical Quality Systems dated 14 October 2005 Endorsed by the ICH SC on 10 November 2005
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Final Business Plan Q10: Pharmaceutical Quality Systems dated 14 October 2005 Endorsed
More informationICH Q10 Pharmaceutical Quality System (PQS)
ICH Q10 Pharmaceutical Quality System (PQS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Q10 PQS Guideline Background Objectives
More informationOutsourcing and the Affiliate Model
Outsourcing and the Affiliate Model Streamlining Processes and Emphasising Strategy REPORT Outsourcing and Consulting Services for Life Sciences www.productlife-group.com Table of Contents Executive Summary...1
More informationQuality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle
Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory
More informationJob description. Job title. Process Engineer. Responsible to. Process Engineering Manager. Hours/sessions per week 37.
Job description Job title Directorate Pay band Responsible to Base/location Process Engineer Production SEO Process Engineering Manager Porton Hours/sessions per week 37.5 Job type Permanent INTRODUCTION
More informationThe Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence
The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence CMC Strategy Forum, Sorrento, May 7th, 2014 Susanne Ausborn, Pharma Technical Regulatory Policy F. Hoffmann-La Roche,
More informationOPER H6001. Pharmaceutical Operations Mgt. APPROVED. Pharmaceutical Operations Management for Engineers. Credits: 5. NFQ Level: 9
Short Title: Full Title: APPROVED Management for Engineers Module Code: OPER H6001 Credits: 5 NFQ Level: 9 Field of Study: Mechanics and metal work Module Delivered in 1 programme(s) Reviewed By: GERARD
More informationQUALITY RISK MANAGEMENT (QRM): A REVIEW
Lotlikar et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 149-154 149 Available online at http://jddtonline.info REVIEW ARTICLE QUALITY RISK MANAGEMENT (QRM): A REVIEW Lotlikar MV Head Corporate
More informationIntroduction to Q10 Pharmaceutical Quality System
ICH-GCG Asean Training Workshop on ICH Guidelines Q8,Q9 and Q10 (New Paradigm) Introduction to Q10 Pharmaceutical Quality System Georges FRANCE, Q- IWG Kuala Lumpur, Malaysia 26-28 July 2010 International
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION
April 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES:
More informationLifecycle CMC Management: ICH Q12 Progress to date
Lifecycle CMC Management: ICH Q12 Progress to date BWP/QWP/GMDP IWG Industry European workshop 28-29 October 2015 Jean-Louis ROBERT (EU) Graham Cook (EFPIA) Please take note The following slides represent
More informationHistory and Principles of Good Clinical Practice
History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices
More informationQbD / PAT Conference 2014
Invitation to The University of Heidelberg Authority Speakers: Karthik Iyer FDA, CDER, USA (via video conference) Dr Øyvind Holte Norwegian Medicines Agency Speakers from Industry and University: Sander
More informationIndustry Implications of Pharmaceutical Quality ICH Guidelines
EIPG General Assembly Industry Implications of Pharmaceutical Quality ICH Guidelines 20 th April 2008 Pharmaceutical Quality Develop a harmonised pharmaceutical quality system applicable across the lifecycle
More informationFit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing
Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing Thursday 08 October 2015 8-9 October 2015, Copenhagen (Denmark) Medicon Valley Alliance,
More informationAPV/IPEC Europe Excipient Conference 2014
APV/IPEC Europe Excipient Conference 2014 An update on regulatory and application developments 23 to 24 September 2014 Düsseldorf, Germany Course No. 3128 Marketing Düsseldorf Target Group This conference
More informationManagement, Supply and Quality Assurance of Clinical Trials
Speakers Brigitte Bastyns Johnson&Johnson Rita Hattemer- Apostel Verdandi AG Andreas Jungk Lawfirm Jungk Helena Lindberg GCP Inspector, Swedish Medical Products Agency Dr Claudio Lorck AbbVie Dr Andreas
More informationHarmonizing Change Control Processes Globally
Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses
More informationComparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
More informationWhat is the correct title of this publication? What is the current status of understanding and implementation?
GMP Rules and Guidelines in 2013 for Computer System Validation / Computerises Systems / Electronic Records and Signatures/ IT Infrastructure and Application Compliance: What is the correct title of this
More informationQuality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011
Quality by Design Approaches to Analytical Methods -- FDA Perspective Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011 1 Outline What is Quality by Design (QbD) Role of Analytical
More informationPrinciples. of Pharmaceutical Facility Design. Full Time Part Time Online. www.dpseng.com.sg
Principles of Pharmaceutical Facility Design Full Time Part Time Online www.dpseng.com.sg Contents 1. Welcome 2. Programme Overview 3. Programme Content www.dpseng.com.sg 2 Welcome Transition into a new
More informationThis interpretation of the revised Annex
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE July/August 2011, Vol. 31 No. 4 www.ispe.org Copyright ISPE 2011 The ISPE GAMP Community of Practice (COP) provides its interpretation
More informationGuidance for Industry
Guidance for Industry Q8, Q9, and Q10 Questions and Answers(R4) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010
ICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010 Joseph C. Famulare Head of External Relations and Collaboration Pharma Global Technical Operations Global Quality, F. Hoffmann-La
More informationOverview. Health Science Authority. Implementation of ICH guideline in Singapore. Singapore s experience
ICH and Singapore Dr Christina Lim Deputy Group Director, Health Product Regulation Group Senior Advisor, International Collaboration Health Sciences Authority Singapore November 2008 Overview Health Science
More informationGMP Issues for Start-Ups, quality in the supply chain and role of the Qualified Person (QP)
GMP Issues for Start-Ups, quality in the supply chain and role of the Qualified Person (QP) Presented by: Patrick Costello Scientific Administrator, European Medicines Agency An agency of the European
More informationQbD Considerations for Analytical Methods - FDA Perspective
QbD Considerations for Analytical Methods - FDA Perspective IFPAC Annual Meeting Baltimore, January 25, 2013 Sharmista Chatterjee, Ph.D. CMC Lead for QbD ONDQA/CDER/FDA Outline Role of analytics in drug
More informationProcess Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases
More informationWorkshop on process validation
Workshop on process validation General concepts on process validation Kowid Ho Scope / background Process evaluation/validation of biotechnology derived proteins used as active substance in the manufacture
More informationThe complexity of today s pharmaceutical
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE This article presents a holistic approach to pharmaceutical manufacturing based on product and process knowledge that allows companies
More informationGRADUATE CERTIFICATE IN GOOD MANUFACTURING PRACTICE (GMP) Plan your career for tomorrow and you will be ahead of your competitors
GRADUATE CERTIFICATE IN GOOD MANUFACTURING PRACTICE (GMP) Plan your career for tomorrow and you will be ahead of your competitors This course is a distance-learning program that will culminate in a Graduate
More informationNew changes to cleanroom & clean air device classifications: ISO 14644 1 & 2
New changes to cleanroom & clean air device classifications: ISO 14644 1 & 2 This white paper describes the changes outlined in the Draft International Standard (DIS) editions of ISO 14644-1 and ISO 14644-2.
More information1. Name of pharmacopoeia
1 1. Name of pharmacopoeia European Pharmacopoeia 36 Member states (Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece,
More informationA NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program
A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry PROJECT MANAGEMENT: RENOVATION OF RESEARCH LABORATORY FOR CELL CULTURE
More informationWorking with ICH Quality Guidelines - the Canadian Perspective
Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction
More informationPresented at: Jefferies 2015 Global Healthcare Conference
Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution
More informationEvent Sponsorship Opportunities
Event Sponsorship Opportunities Creating Value for Your Company Sponsoring Medicon Valley Alliance provides you with unique access to life science professionals in Denmark and Sweden. Through a range of
More informationGMP and QMS Regulation in Japan
GMP and QMS Regulation in Japan Tomiko Tawaragi Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA) August 2 nd, 2014 1 st Brazil-Japan Seminar GMP/QMS GMP : Good Manufacture Practice
More informationFDA Guidance for Industry Update - Process Validation
FDA Guidance Update: Process Validation: General Principles and Practices White Paper FDA Guidance for Industry Update - Process Validation The changing face of Validation; are IQ, OQ and PQ really dead
More informationICH guideline Q8, Q9 and Q10 - questions and answers volume 4
December 2010 EMA/CHMP/ICH/265145/ Committee for medicinal products for human use (CHMP) ICH guideline Q8, Q9 and Q10 - questions and answers volume 4 Step 5 Transmission to CHMP for information December
More informationMonitoring. Compliant and Reasonable. 5-6 May 2015, Berlin, Germany
Environmental Monitoring Workshops How to Establish an Environmental Monitoring Programme Interpretation of OOS Results Compliant and Reasonable 5-6 May 2015, Berlin, Germany SPEAKERS: Oxoid, UK Sauflon
More informationGMP Facility Design with Good Engineering Practice
National University of Singapore Academy of GxP Excellence (NUSAGE) and PharmEng Technology Presents GMP Facility Design with Good Engineering Practice Part of the Pharmaceutical and Biotechnology Training
More informationThere is no Silver Bullet to complying with the US FDA GMPs by Alan Schwartz
There is no Silver Bullet to complying with the US FDA GMPs by Alan Schwartz Recently, we participated in a seminar on United States (US) Food and Drug Administration (FDA) regulations to the Hebei Pharmaceutical
More informationPHARMACEUTICAL REFERENCE STANDARDS
PHARMACEUTICAL REFERENCE STANDARDS 11 th International Symposium organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe 3-4 September 2012, Strasbourg,
More information2010 Critical Thinker Series
Malaysian Organisation of Pharmaceutical Industries (MOPI) & PharmEng Technology Presents cgmp Case Studies a T rra ini ing i P rrog rram ffo rr cgmp P rro ffe ss ss ionai l ss 2010 Critical Thinker Series
More informationUNICEF s Quality Assurance System for Procurement of Micronutrient Powders (MNP)
UNICEF s Quality Assurance System for Procurement of Micronutrient Powders (MNP) Nutrition Supplier Meeting, June 30, 2015 Dimitris Catsoulacos Quality Assurance Specialist PRESENTATION OVERVIEW Quality
More informationBiometrics: Clinical Trials and Beyond
Biometrics: Clinical Trials and Beyond Statistics, Programming, and Data Management in Research, Development, and Regulatory Submissions. For all, Not Just Statisticians! Keynote Presentations Sue-Jane
More informationPURE and APPLIED CHEMISTRY
SS PURE and APPLIED CHEMISTRY PURE and APPLIED CHEMISTRY Why is Chemistry Important? The challenge facing chemists is to understand how and why substances behave as they do through detecting molecules,
More information20-21 May 2015, Lisbon, Portugal. Highlights. Speakers:
Speakers: Dr Afshin Hosseiny Chair of the ECA Expert Working Group on GDP, Tabriz Consulting Comply with the new EU GDP Guideline Dr Martin Egger Pharmaserv Dr Daniel Müller GMP/GDP Inspector All participants
More informationGuidance for Industry
Guidance for Industry Process Validation: General Principles and Practices U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
More informationImpact Assessment in a Science & Risk Based Environment. R. Legland 11/04/11
Impact Assessment in a Science & Risk Based Environment R. Legland 11/04/11 Background US GMP s EU GMP s Japan GMP s ICH Q8, Q9, Q10 Guidance ASTM Standard E2500-07 Science and Risk Based Approach to Determine
More informationContinuous manufacturing moving towards real-time release. Creating innovations for the pharmaceutical industry. siemens.
Continuous manufacturing moving towards real-time release Creating innovations for the pharmaceutical industry siemens.com/pharma Strategic partnership Creative ideas and industry expertise A move to continuous
More informationQuality Thinking in other Industries. Dominic Parry Inspired Pharma Training. WEB www.inspiredpharma.com GMP BLOG inspiredpharmablog.
Quality Thinking in other Industries Dominic Parry Inspired Pharma Training WEB www.inspiredpharma.com GMP BLOG inspiredpharmablog.com Welcome The traditional focus on quality Quality in the eyes of GMP
More informationGMP/Regulatory Environment in the
GMP/Regulatory Environment in the Latin America Irene Ortiz Barreal, Pharm. D., R.Ph. Pfizer International Affiliate Quality Compliance Regional Leader Latin America/Caribbean April 14, 2011 Discloser
More informationBioForum 2012 Central European Forum of Biotechnology and Innovative BioEconomy 23rd-24th May 2012, Brno Date & Venue Date Venue
BioForum 2012 Central European Forum of Biotechnology and Innovative BioEconomy 23 rd -24 th May 2012, Brno www.cebioforum.com Author: Edyta Wodzińska Bio-Tech Consulting 1 Date & Venue Date: May 23 rd
More informationEMA Article 57 Planned Evolution
Though many points remain open, we have at least some indications about how the European Agency intends to proceed: Published February 17, 2015 EMA Article 57 Planned Evolution Article 25 and 26 of Commission
More informationGuidance for Industry: Quality Risk Management
Guidance for Industry: Quality Risk Management Version 1.0 Drug Office Department of Health Contents 1. Introduction... 3 2. Purpose of this document... 3 3. Scope... 3 4. What is risk?... 4 5. Integrating
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY VERSION 7
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems and products Medicinal products quality, safety and efficacy Brussels, IMPORTATION OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS
More informationWhite paper: FDA Guidance for Industry Update Process Validation
White paper: FDA Guidance for Industry Update Process Validation In January 2011, the FDA released the final version of its long-awaited update to its Process Validation Guidance for Industry. Since then,
More informationAuditing as a Component of a Pharmaceutical Quality System
Auditing as a Component of a Pharmaceutical Quality System Tim Fields Conducting internal audits (or self inspections) and external audits of suppliers and outsourcing operations are key elements of a
More informationMerck: Revitalizing Master-Data Management
2013 SAP AG or an SAP affiliate company. All rights reserved. Merck: Revitalizing Master-Data Management Partner Merck KGaA Industry Pharmaceuticals, Chemicals & Life Sciences Products and Services Pharmaceutical
More informationHighly Potent APIs The right platform, people and procedures for successful development and manufacturing
Pharma&Biotech Highly Potent APIs The right platform, people and procedures for successful development and manufacturing Custom Manufacturing and Development Services for Highly Potent APIs Pharma&Biotech
More informationISPE Nordic Conference Sustainability in the Pharmaceutical Industry Copenhagen, Denmark. www.ispe.org
ISPE Nordic Conference Sustainability in the Pharmaceutical Industry Copenhagen, Denmark To be held at AC Hotel Bella Sky Copenhagen Thursday 21 May, 2015 www.ispe.org Ensuring supply security and license
More information